Abstract
Previous clinical studies on the prevention of atherosclerosis with probiotics aimed only for the reduction of blood lipids. The aim of this study was to investigate the effect of probiotic Bifidobacterium animalis subsp. lactis LKM512 on colonic trimethylamine (TMA) and atherosclerosis-related markers in healthy subjects. Twenty-seven subjects (average age, 47.1years) were assigned to receive probiotics or placebo for 12weeks. At week 12, the fecal TMA concentration and BMI in the probiotics group was lower than that in the placebo group (p<0.05) and the relative abundance of specific bacterial groups (Clostridia, Clostridiales, and Lachnospiraceae), including TMA-producing bacteria, in the probiotics group was lower than that in the placebo group (p<0.05). The serum TNF-α concentration decreased (p<0.01) in the probiotics group only. Thus, probiotic LKM512 could reduce the risk of arteriosclerosis development in healthy subjects via reduction of TMA produced by intestinal microbiota.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
